Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

Abstract

Evidence-based guidelines will help to optimise treatment outcomes with ranibizumab in neovascular AMD.

Retinal and Choroidal Thickness in Early Age-Related Macular Degeneration

“…Pigment Epithelial Detachment (PED). 4 . "Early" or "Wet" denotes the subtype of age-related macular degeneration.…”

PlGF: A Multitasking Cytokine with Disease-Restricted Activity

“…Choroidal neovascularization (CNV) in patients with the wet form of age-related macular degeneration (AMD) is another prevalent cause of visual loss, especially in the elderly (Mitchell et al 2010). PlGF is elevated in human AMD and mouse models of laser-induced CNV (Rakic et al 2003;Huang et al 2011), whereas PlGF gene deficiency in mice reduces experimental CNV (Rakic et al 2003).…”

A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

“…1 Although anti-VEGF therapies inhibit growth and permeability of new vessels and help prevent early CNV development, multiple retreatments are needed in most cases, and established CNV may be resistant to VEGF inhibition. 2 Photodynamic therapy (PDT) with verteporfin has been shown to occlude established CNV, but causes increased VEGF expression, which may lead to CNV recurrence.…”